Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaWAR:SPH 67 Forward PE Ratio is 13.02 as of Jul. 28, 2026. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.34 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 51 Medical Distribution companies, Sopharma AD-Sofia ranks better than 56.86% on this metric.
Sopharma AD-Sofia (WAR:SPH) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Sopharma AD-Sofia Forward PE Ratio Related Terms
Sopharma AD-Sofia Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia Forward PE Ratio Chart
Sopharma AD-Sofia Annual Data
Trend
Forward PE Ratio
Sopharma AD-Sofia Quarterly Data
2024-03
Forward PE Ratio
10.86
WAR:SPH vs MCK, COR, CAH: Forward PE Ratio Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Forward PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Sopharma AD-Sofia (WAR:SPH) has a Forward PE Ratio of 13.02 as of Jul. 28, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #22 out of 51 companies in the Medical Distribution industry, placing it in the top 43.1%.
Is Sopharma AD-Sofia's Forward PE Ratio too high?
Sopharma AD-Sofia's current Forward PE Ratio is 13.02. The Medical Distribution industry median Forward PE Ratio is 14.52. Sopharma AD-Sofia's value of 13.02 is 10.3% below this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #22 out of 51 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Forward PE Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #22 out of 51 companies for Forward PE Ratio. This puts Sopharma AD-Sofia in the upper half of its industry. The industry median Forward PE Ratio is 14.52. Sopharma AD-Sofia's value of 13.02 is 10.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.52, based on 51 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Forward PE Ratio of 13.02 is 10.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Forward PE Ratio is 13.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.34, compared to a current price of zł7.56 — trading 43.3% below its estimated fair value. The current Forward PE Ratio is 13.02 and 10.3% below the Medical Distribution industry median of 14.52. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Forward PE Ratio is 13.02 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.56 is trading 43.3% below its estimated GF Value™ of zł13.34.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Forward PE Ratio: 13.02
GF Value™: zł13.34 vs. price of zł7.56 (43.3% below fair value)
Industry Position: 10.3% below the Medical Distribution median (#22 of 51)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
